ALXN2220-ATTRCM-301: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Brief description of study
We are doing this study to learn more about an experimental drug called ALXN2220 for the proposed treatment of adult patients with ATTR-CM, and to better understand the studied disease and associated health problems.
Experimental means ALXN2220 has not been fully tested in patients with ATTR-CM yet, and it is not approved by any health authority, except for use in research studies like this one.
Clinical Study Identifier: s23-01377
ClinicalTrials.gov Identifier: NCT06183931
Principal Investigator:
Jose A Alvarez-Cardona.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.